KRAS and cancer: Taken together, we propose that, in addition to inhibiting mutant KRAS, the anti-cancer effect of G12Ci drugs is also mediated by the electrophile-mediated induction of NRF2, which results in induction of NISP expression, and the concomitant promotion of the anti-cancer immune response (Fig. 2r).